| Budget Amount *help |
¥87,620,000 (Direct Cost: ¥67,400,000、Indirect Cost: ¥20,220,000)
Fiscal Year 2014: ¥16,510,000 (Direct Cost: ¥12,700,000、Indirect Cost: ¥3,810,000)
Fiscal Year 2013: ¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2012: ¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2011: ¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2010: ¥18,200,000 (Direct Cost: ¥14,000,000、Indirect Cost: ¥4,200,000)
|
|---|
| Outline of Final Research Achievements |
In order to analyze HER2/ErbB2-PI3K-NFkB pathway in breast cancer stem cells, DNA microarray analysis was performed by using breast cancer cells stimulated with HER2 in the presence or absence of NFkB inhibitor or PI3K inhibitor. We identified several candidate molecular targets in breast cancer stem cells, IGF2, AR, GDF15, for example. We confirmed that these molecules play important roles for stemness of breast cancer cells.
We analyzed FRS2beta knockout mice in the background of MMTV-ErbB2 mammary tumor model. We found that FRS2beta play important roles for stemness of mammary tumors through fine-tuning of ErbB2 signaling.
|
